NCT07123779View on ClinicalTrials.gov

Study of HS235 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2028

Conditions
Pulmonary HypertensionHeart Failure With Preserved Ejection Fraction
Interventions
BIOLOGICAL

HS235

Subcutaneous Injection

OTHER

Placebo

Subcutaneous Injection

Sponsors

Lead Sponsor

35Pharma Inc
All Listed Sponsors
lead

35Pharma Inc

INDUSTRY